by Mark Curtis | Dec 10, 2015
Welcome to your Update from the Clinic for the month of November. There were a number of mid-stage clinical trials launched by cell-based immunotherapy companies this past month, furthering a robust global pipeline of CAR/TCR products. We also saw some efficacy data...
by Mark Curtis | Nov 24, 2015
Welcome to your Cell Therapy Deal Review for the month of October. Lion Biotechnologies and Kite Pharma both made deals with the National Institutes of Health (NIH) that significantly expanded their respective pipelines. Kite also announced a research collaboration...
by Hamideh Emrani | Nov 4, 2015
Among many interesting talks at this year’s Till and McCulloch Meetings in Toronto, Canada, there were a couple related to biomaterials, which I’d like to focus on. In the first talk, professor Milica Radisic, University of Toronto, talked about two recent...
by Mark Curtis | Oct 27, 2015
Welcome to your Update from the Clinic for the month of September. OncoSec Medical released some initial data from its Phase 1/2 study investigating ImmunoPulse IL-12 DNA in a rare skin cancer. Pluristem and the National Institute of Allergy and Infectious Diseases...
by Mark Curtis | Oct 20, 2015
. Welcome to your Cell Therapy Deal Review for the month of September. Aduro Biotech went the way of Juno and Kite and bought an antibody discovery platform. Intrexon and ZIOPHARM entered into an agreement to develop a novel Treg-based immunotherapy for GvHD. Kite...
Comments